Bourgeon Capital Management LLC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 9.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,672 shares of the company’s stock after selling 10,548 shares during the quarter. Merck & Co., Inc. comprises approximately 4.8% of Bourgeon Capital Management LLC’s holdings, making the stock its biggest holding. Bourgeon Capital Management LLC’s holdings in Merck & Co., Inc. were worth $7,310,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of MRK. Bank of New York Mellon Corp lifted its holdings in shares of Merck & Co., Inc. by 184,252.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 38,985,039 shares of the company’s stock valued at $2,765,600,000 after acquiring an additional 38,963,892 shares in the last quarter. Capital International Investors lifted its holdings in Merck & Co., Inc. by 178.2% in the 3rd quarter. Capital International Investors now owns 32,984,606 shares of the company’s stock worth $2,339,928,000 after buying an additional 21,127,887 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Merck & Co., Inc. by 64.3% in the 3rd quarter. Janus Henderson Group PLC now owns 20,519,549 shares of the company’s stock worth $1,455,653,000 after buying an additional 8,032,634 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its holdings in Merck & Co., Inc. by 5,970.0% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 5,369,519 shares of the company’s stock worth $88,460,000 after buying an additional 5,281,059 shares in the last quarter. Finally, Senator Investment Group LP acquired a new position in Merck & Co., Inc. in the 2nd quarter worth $285,594,000. Institutional investors and hedge funds own 74.29% of the company’s stock.
MRK opened at $79.02 on Thursday. The stock has a market capitalization of $209.82 billion, a PE ratio of 18.21, a P/E/G ratio of 2.05 and a beta of 0.62. Merck & Co., Inc. has a 1-year low of $52.83 and a 1-year high of $80.19. The company has a quick ratio of 1.15, a current ratio of 1.44 and a debt-to-equity ratio of 0.61.
Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.01. The company had revenue of $11 billion during the quarter, compared to the consensus estimate of $10.93 billion. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 35.10%. The company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.98 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 4.65 EPS for the current year.
Merck & Co., Inc. announced that its Board of Directors has authorized a share repurchase plan on Thursday, October 25th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to buy up to 5.1% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.78%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is currently 50.69%.
In other news, Director Thomas H. Glocer sold 10,000 shares of the business’s stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $75.96, for a total value of $759,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leslie A. Brun sold 3,052 shares of the business’s stock in a transaction dated Friday, February 8th. The shares were sold at an average price of $77.22, for a total transaction of $235,675.44. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $386,100. The disclosure for this sale can be found here. Insiders sold a total of 244,618 shares of company stock valued at $19,075,949 in the last three months. Insiders own 0.32% of the company’s stock.
A number of brokerages have commented on MRK. Zacks Investment Research lowered shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 24th. BMO Capital Markets lowered shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective on the stock. in a report on Wednesday, January 23rd. Citigroup set a $65.00 price objective on shares of Merck & Co., Inc. and gave the stock a “hold” rating in a report on Thursday, December 20th. Morgan Stanley set a $81.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, December 20th. Finally, Credit Suisse Group set a $86.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, December 13th. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Merck & Co., Inc. presently has an average rating of “Buy” and an average price target of $73.15.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Featured Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.